Akeso (SEHK:9926) Could Be 41% Undervalued On Phase II Breast Cancer Trial Progress

Akeso (SEHK:9926) has just reached a fresh clinical milestone. The company has dosed the first patient in a Phase II trial of its TROP2/Nectin-4 ADC AK146D1 in combination with ivonescimab for advanced breast cancer.

See our latest analysis for Akeso.

Akeso's latest trial update comes after a mixed period for the stock, with a 7 day share price return of 8.58% and a 30 day share price return of 4.78%, but a 90 day share price return that declined 19.95%. Over longer horizons, total shareholder return has declined 34.89% over 1 year yet remains well ahead of its listing level with a 3 year total shareholder return of about 3x. This suggests recent momentum has cooled compared with earlier gains.

If Akeso's IO2.0 + ADC2.0 pipeline has caught your attention, it can be useful to see what else is developing in oncology and beyond through a curated set of healthcare focused AI plays such as 130 healthcare AI stocks

Akeso shares have bounced over the past week but remain well below their 1 year level. For investors watching this IO2.0 plus ADC2.0 story, the question is whether it makes more sense to wait for greater clarity or to start valuing the opportunity now.

Most Popular Narrative: 40.9% Undervalued

Akeso's most followed narrative points to a fair value of HK$172.32 versus the last close at HK$101.9. This frames the recent trial news against a much higher implied value anchored on long term earnings and cash flow assumptions.

The company's strong R&D pipeline, including advanced bispecific antibodies and ADC candidates, provides a foundation for long-term growth, setting the stage for potential increases in net margins as products move from development to commercialization.

Read the complete narrative.

Want to see what is baked into that fair value for Akeso? The narrative leans on rapid revenue expansion, a sharp profit margin swing and a rich future earnings multiple. Curious how those ingredients are combined into one price target?

Result: Fair Value of HK$172.32 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Akeso still carries real execution risk, including ongoing operating losses, as well as heavy reliance on a handful of key drugs and external partnerships.

Find out about the key risks to this Akeso narrative.

Another View On Akeso’s Valuation

While the narrative and analyst targets point to Akeso trading below fair value, the current P/S ratio of 26.4x tells a different story. It is well above the Hong Kong Biotechs average of 11.6x and even the fair ratio of 14.7x. This richer multiple may indicate either additional upside potential or a higher valuation risk for investors watching the story unfold.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed sentiment around Akeso's valuation and pipeline can be hard to interpret, so it helps to review the data directly and decide where you stand. To see what supporters of the stock are focusing on, take a closer look at its 2 key rewards

Looking For More Investment Ideas Beyond Akeso?

If Akeso has sharpened your interest in healthcare and growth stories, do not stop here. Broaden your watchlist with other focused ideas that could round out your portfolio.

• Target potential mispricings by scanning a curated list of companies that screen as 262 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks highlighted as 440 dividend fortresses.
• Dial down portfolio risk by focusing on companies flagged in the 297 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com